NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar
12 January 2026
1 min read

NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

New York, January 12, 2026, 05:15 EST — Premarket

  • Shares of NovaBay Pharmaceuticals slipped roughly 10% in premarket action.
  • The stock surged past double its previous level on Friday, trading about 10 million shares.
  • Traders are eager for new updates on warrants, conversions, and the share supply.

NovaBay Pharmaceuticals, Inc. shares slipped roughly 10% in early Monday trading, falling to $17.21 after finishing Friday at $19.16. This dip comes after a notable surge in the lightly traded stock on the NYSE American. 1

Friday’s surge was extreme, even for a microcap. Shares closed up 102.5%, swinging between $9.69 and $19.95, on roughly 10 million shares changing hands, according to StockAnalysis data. 2

This is crucial now, as the stock has morphed into a momentum play within just a few sessions. Such trades hinge heavily on share availability. With thin liquidity, prices can jump sharply on minimal volume—and then flip direction just as quickly.

According to StockAnalysis data, the 20-day average volume stands near 3.0 million shares, with the float hovering around 12.4 million shares. This combination often magnifies both squeezes and selloffs during volume surges. 3

Traders keep focusing on the company’s capital structure. In an October filing, NovaBay revealed it sold pre-funded warrants for roughly 5.4 million shares, exercisable after Jan. 1, 2026, pending stockholder approval. The company also noted shareholders authorized the board to execute a reverse stock split anywhere from 1-for-2 up to 1-for-10. 4

NovaBay revealed in its latest quarterly filing that it had once considered winding down but decided against it. The company is now exploring a pivot toward “emerging financial infrastructure and network-based markets,” with a particular interest in select blockchain-based assets. It also noted that its cash reserves should cover operating costs through at least Nov. 7, 2026. 5

NovaBay hasn’t released any new comments on the recent stock moves, leaving traders to interpret volume, spreads, and any upcoming disclosures ahead of the open.

But the setup works both ways. Pre-market trading often sees thin volume and wider spreads. Plus, any hint that more shares might enter the market—whether from warrant exercises, preferred stock conversions, or other issuances—can quickly shift the equation for a stock that’s already surged dramatically in a short span.

When the regular session kicks off at 9:30 a.m. EST, traders will focus on whether the stock can maintain last week’s key levels and if the volume remains strong or tapers off.

NovaBay’s fourth-quarter 2025 earnings are expected to drop on March 25, according to MarketScreener. 6

Stock Market Today

Sungrow Power Supply (300274.SZ) A-shares: Monday watch after “commercial space” denial

Sungrow Power Supply (300274.SZ) A-shares: Monday watch after “commercial space” denial

8 February 2026
Sungrow closed at 144.50 yuan, down 1.03%, after stating it has no plans in the commercial space sector. Mainland China trading resumes Monday, with Spring Festival closures set for Feb. 15–23. Major funds were net sellers of 5.46 billion yuan on Feb. 6. The Shenzhen-listed solar firm remains under scrutiny as investors await further filings before the holiday.
MPWR stock price hits a new high after Monolithic Power’s outlook — what traders watch next week

MPWR stock price hits a new high after Monolithic Power’s outlook — what traders watch next week

8 February 2026
Monolithic Power Systems shares surged 6.4% to $1,229.82 Friday, hitting a new 52-week high after raising its dividend to $2.00 and forecasting first-quarter revenue of $770 million to $790 million. CEO Michael Hsing filed a Rule 144 notice for 3,082 shares. CFO Bernie Blegen will retire after the 2025 annual report, with Rob Dean named interim CFO. Fourth-quarter revenue rose 20.8% to $751.2 million.
Microchip Technology stock price: MCHP heads into Monday after earnings outlook and mixed analyst calls

Microchip Technology stock price: MCHP heads into Monday after earnings outlook and mixed analyst calls

8 February 2026
Microchip Technology shares fell 2.6% to $76.01 Friday after its outlook and analyst reactions disappointed some investors. The company reported fiscal Q3 net sales up 15.6% to $1.186 billion and guided March-quarter sales to $1.24–$1.28 billion. A global memory shortage has disrupted orders, and analysts remain split on recovery prospects. BlackRock disclosed a 10% stake as of Jan. 31.
Renesas stock price jumps again as $3 billion SiTime deal keeps traders hooked on 6723

Renesas stock price jumps again as $3 billion SiTime deal keeps traders hooked on 6723

8 February 2026
Renesas shares closed at 2,957.5 yen on Friday, up 6.9% after announcing a $3 billion cash-and-stock deal to transfer its timing business to SiTime, with closing targeted by end-2026. Renesas forecast March-quarter revenue of 367.5–382.5 billion yen and a 58.5% gross margin. The company reported 2025 revenue of 1.32 trillion yen and a non-GAAP profit of 329.3 billion yen.
Barclays stock slides on Trump’s 10% credit-card rate cap call as investors size up profit hit
Previous Story

Barclays stock slides on Trump’s 10% credit-card rate cap call as investors size up profit hit

Mereo BioPharma stock steadies premarket as JPM Healthcare Conference puts MREO back in play
Next Story

Mereo BioPharma stock steadies premarket as JPM Healthcare Conference puts MREO back in play

Go toTop